HopeStage
Back to all studies
CompletedNCT05615948

Aspirin and ketamine added to treatment-resistant depression care

About this titleRead the official source — NCT05615948
Medication studyAges 18–89United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 89 years.

Listed locations
BrooklynSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 6, 2022
Recruitment status
Completed
Enrollment listed in the registry
15
Sponsor
Theresa Jacob, PhD, MPH
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 89 Years
Official registry ID
NCT05615948
Official title
Show the full official title

An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Brooklyn

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Theresa Jacob, PhD, MPH.

Did this study involve medication?

Yes. The study involved medication, including VTS-K.

Who was this study for?

Listed age limits: 18 years to 89 years.

Want to explore more studies?

Explore studies